
    
      This is an open-label (volunteer and study staff will know the identity of study drugs
      assigned) study of canagliflozin and rifampin taken in a sequential order by healthy
      volunteers for up to 12 days. Healthy volunteers will take orally (by mouth) one 300 mg
      canagliflozin tablet and/or two 300 mg rifampin capsules daily in sequential order as
      follows: on Day 1 volunteers will take one 300-mg canagliflozin tablet, on Days 4 to 9
      volunteers will take two 300-mg rifampin capsules once daily, on Day 10 volunteers will take
      one 300-mg canagliflozin tablet + two 300-mg rifampin capsules, and on Days 11 and 12
      volunteers will take two 300-mg rifamplin capsules once daily.
    
  